- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03231839
Nutritional Prevention of Diabetes Mellitus Type 2 (NUPREDM)
July 24, 2017 updated by: andreas fritsche, University Hospital Tuebingen
Identification of Factors Predicting the Success of a Nutritional Intervention to Decrease the Risk of Type 2 Diabetes
This study investigates the influence of red meat and fibers on glucose metabolism and body fat composition in subjects at increased risk for type 2 diabetes.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The epidemiologic evidence for increased red meat intake and decreased fiber intake as risk factors for T2D is solid.
However, few intervention studies have been performed in order to investigate the role of whole-grain intake or the consumption of red meat in glycemic control and prevention of diabetes, yielding contradicting results.
Thus, in order to prove causality, further identify potential underlying mechanisms and be able to improve lifestyle modification programs, we performed a randomized, controlled intervention study over six months.
The participants are individuals at increased risk for tyoe 2 diabetes.
They were randomised to 3 interventions groups: 1) caloric restriction of 400 kcal/day (control group), 2) caloric restriction plus no red meat consumption 3) caloric restriction and increase in fiber intake.
Subjects where thoroughly phenotyped by anthropometric parameters, oral glucose tolerance tests, and MRI measurements of body fat composition and iron content in the liver.
In this study, we want to compare the effectiveness of reduced caloric intake only versus reduced caloric intake with an additional modification of diet composition in terms of red meat and fiber consumption.
Study Type
Interventional
Enrollment (Actual)
132
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Tuebingen, Germany, 72074
- University of Tuebingen
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
Individuals at a high risk for Type 2 diabetes:
- positive family history of type 2 diabetes,
- presence of metabolic syndrome,
- body mass index (BMI) > 27 kg/m2,
- diagnosis of impaired glucose tolerance (IGT)
- previous diagnosis of gestational diabetes diabetes
Exclusion Criteria:
Main exclusion criteria
- diagnosis of type 1 or 2 diabetes mellitus
- BMI >45 kg/m²
- presence of serious illness such as cardiovascular, malignant or psychiatric disease.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Caloric restriction (control)
daily reduction of caloric intake aimed at 400 kcal/day
|
After the baseline measurements individuals underwent dietary counseling and had 6 sessions with a dietician (after, 1,4,8,12 16 and 20 weeks).
|
Active Comparator: No red meat
daily reduction of caloric intake aimed at 400 kcal/day plus no red meat intake
|
After the baseline measurements individuals underwent dietary counseling and had 6 sessions with a dietician (after, 1,4,8,12 16 and 20 weeks).
|
Active Comparator: Increased fiber intake
daily reduction of caloric intake aimed at 400 kcal/day plus increased fiber intake (aim: 40gr/day)
|
After the baseline measurements individuals underwent dietary counseling and had 6 sessions with a dietician (after, 1,4,8,12 16 and 20 weeks).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
change in glucose metabolism
Time Frame: baseline and six months
|
glucose metabolism measured during the oral glucose tolerance test (OGTT)
|
baseline and six months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Insulin secretion
Time Frame: baseline and six months
|
Disposition index (insulin sensitivity (Matsuda) x insulinogenic index (IGI))
|
baseline and six months
|
liver fat
Time Frame: baseline and six months
|
measured by magnetic resonance spectroscopy
|
baseline and six months
|
liver iron content
Time Frame: baseline and six months
|
measured by magnetic resonance imaging
|
baseline and six months
|
body composition
Time Frame: baseline and six months
|
measured by magnetic resonance imaging
|
baseline and six months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 1, 2009
Primary Completion (Actual)
June 30, 2012
Study Completion (Actual)
July 31, 2016
Study Registration Dates
First Submitted
July 24, 2017
First Submitted That Met QC Criteria
July 24, 2017
First Posted (Actual)
July 27, 2017
Study Record Updates
Last Update Posted (Actual)
July 27, 2017
Last Update Submitted That Met QC Criteria
July 24, 2017
Last Verified
July 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- UTubingen4
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
IPD Plan Description
Not allowed by ethics committee
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 2 Diabetes Mellitus
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
AstraZenecaRecruiting
-
Daewoong Pharmaceutical Co. LTD.Not yet recruitingT2DM (Type 2 Diabetes Mellitus)
-
Zhongda HospitalRecruitingType 2 Diabetes Mellitus (T2DM)China
Clinical Trials on Caloric restriction
-
PfizerUniversity of Adelaide; Royal Adelaide HospitalCompleted
-
Federal University of Minas GeraisRecruiting
-
Karolinska University HospitalCompleted
-
Centre d'Alt RendimentCompleted
-
Korea UniversityEulji University HospitalCompletedOverweight | Type 2 DiabetesKorea, Republic of
-
University Hospital, MontpellierUnknownType 2 Diabetes | Severe ObesityFrance
-
Federico II UniversityFondazione Italiana Sclerosi MultiplaRecruitingMultiple Sclerosis, Relapsing-Remitting | Caloric RestrictionItaly
-
Wake Forest University Health SciencesActive, not recruiting
-
Pennington Biomedical Research CenterNational Institute on Aging (NIA)Completed
-
Central Hospital, Nancy, FranceRecruitingCrohn's DiseaseFrance